Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants. The coagulation enzyme Factor Xa (FXa) is a particularly promising anticoagulant target. BAY 59-7939 (5), a highly potent and selective, demonstrated direct FXa inhibitor. Compound 5 is currently under clinical development for the prevention and treatment of thromboembolic diseases.
This biologic model of Factor Xa in Complex with Small Molecule Inhibitor is 3D printed in full-color sandstone.
Select the desired material finish and size below. Matte finish applies a UV protective, semi-glossy coating.